Alexander Drilon
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
-
- Lung Cancer Treatments and Mutations 268
- Sarcoma Diagnosis and Treatment 36
-
- Cancer Genomics and Diagnostics 61
- Co-authors
- Marc Ladanyi (40 shared papers)Emiliano Cocco (6 shared papers)Maurizio Scaltriti (5 shared papers)Maria Arcila (26 shared papers)Mark G. Kris (27 shared papers)Natasha Rekhtman (16 shared papers)Charles Rudin (21 shared papers)Ryma Benayed (16 shared papers)
- Journals
- Annals of Oncology (70 papers)Journal of Thoracic Oncology (38 papers)Clinical Cancer Research (31 papers)JCO Precision Oncology (22 papers)Cancer Discovery (20 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Alexander Drilon
350 papers receiving 29.5k citations
Alexander Drilon's Hit Papers
Peers
Comparison fields: 5 of 120
- Pulmonary and Respiratory Medicine 16.2k
- Cancer Research 4.3k
- Oncology 5.5k
- Pathology and Forensic Medicine 2k
- Endocrinology, Diabetes and Metabolism 1.9k
Countries citing papers authored by Alexander Drilon
This map shows the geographic impact of Alexander Drilon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Drilon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Drilon more than expected).
Fields of papers citing papers by Alexander Drilon
This network shows the impact of papers produced by Alexander Drilon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Drilon. The network helps show where Alexander Drilon may publish in the future.
Co-authors
The 25 scholars most cited alongside Alexander Drilon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 362 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children Hit paper breakdown → | 2018 | 2136 |
| 2 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Hit paper breakdown → | 2019 | 1350 |
| 3 | NTRK fusion-positive cancers and TRK inhibitor therapy Hit paper breakdown → | 2018 | 1146 |
| 4 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry Hit paper breakdown → | 2019 | 1066 |
| 5 | Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials Hit paper breakdown → | 2020 | 814 |
| 6 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Hit paper breakdown → | 2017 | 680 |
| 7 | HER kinase inhibition in patients with HER2- and HER3-mutant cancers Hit paper breakdown → | 2018 | 629 |
| 8 | Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 617 |
| 9 | Efficacy of Selpercatinib in RET -Altered Thyroid Cancers Hit paper breakdown → | 2020 | 593 |
| 10 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies Hit paper breakdown → | 2017 | 541 |
| 11 | Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping Hit paper breakdown → | 2015 | 491 |
| 12 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 488 |
| 13 | Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial Hit paper breakdown → | 2018 | 474 |
| 14 | NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls Hit paper breakdown → | 2019 | 428 |
| 15 | Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations Hit paper breakdown → | 2018 | 418 |
| 16 | Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas Hit paper breakdown → | 2013 | 403 |
| 17 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials Hit paper breakdown → | 2019 | 403 |
| 18 | Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial Hit paper breakdown → | 2016 | 386 |
| 19 | Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions Hit paper breakdown → | 2017 | 382 |
| 20 | 2016 | 381 |
About Alexander Drilon
Alexander Drilon is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Pathology and Forensic Medicine and Endocrinology, Diabetes and Metabolism, having authored 362 papers that have together received 30.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (268 papers), Cancer Genomics and Diagnostics (61 papers), Sarcoma Diagnosis and Treatment (36 papers), Cancer Mechanisms and Therapy (24 papers), Cancer Immunotherapy and Biomarkers (22 papers), Thyroid Cancer Diagnosis and Treatment (16 papers), Glioma Diagnosis and Treatment (11 papers) and HER2/EGFR in Cancer Research (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (16.2k citations), Cancer Research (4.3k citations), Oncology (5.5k citations), Pathology and Forensic Medicine (2k citations) and Endocrinology, Diabetes and Metabolism (1.9k citations). Alexander Drilon has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Marc Ladanyi, Emiliano Cocco, Maurizio Scaltriti, Maria Arcila, Mark G. Kris, Natasha Rekhtman, Charles Rudin, Ryma Benayed, David Michael Hyman and Alison M. Schram. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, Clinical Cancer Research, JCO Precision Oncology and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.